Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07469800) titled 'Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity' on Feb. 27.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Condition:
Overweight
Obesity
Hypertensive
Intervention:
Drug: IBI362
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: April 1, 2026
Target Sample Size: 336
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT07469800
...